The triple-negative classification refers to breast tumors lacking expression of the receptors ER (estrogen receptor), PR (progesterone receptor), and HER2/neu (human epidermal growth factor receptor 2) [3,4], which are commonly used as therapeutic targets for systemic treatments. Here, ERBB2 is linked to breast neoplasm.